Pharmaceutical giant Merck’s (NYSE:MRK) pembrolizumab drug, Keytruda, has been granted an additional indication by the Food and Drug Administration (FDA) for non-small cell lung cancer (NSCLC) treatment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The statement said that the new indication is for NSCLC patients who have already undergone resection and platinum-based chemotherapy.
According to the statement, Keytruda is a programmed death receptor-1-blocking antibody that is indicated “in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.”
Keytruda is one of Merck’s biggest top-line drivers and is already approved for the treatment of many cancers globally. Earlier this week, Merck reported ‘positive’ results from its Phase 3 KEYNOTE-966 trial. Refinitiv data suggests that Keytruda revenues are expected to surpass $30 billion in 2026 and $35 billion by 2028 on average.
Is MRK a Buy or Sell?
Wall Street is bullish on MRK stock, with a Strong Buy consensus rating based on 13 Buys and four Holds. The average price target of $117.47 indicates a 9.92% upside over the year.